OUT COME RESULTS AND SCRUTINIZER REPORTS
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek held its 35th AGM on 30 December 2025 via video conferencing, where all 7 resolutions were passed. Total votes polled were 16,837,587, representing about 22.22% of the company's 7.57 crore outstanding shares, with only 50 shareholders casting votes via remote e-voting. The audited financial statements for FY ending 31 March 2025 were adopted with 99.99% support, and director re-appointments (including Mr. Santhosh Kumar by rotation) and three independent director re-appointments passed with near-unanimous approval. The re-appointment of Dr. K. Koteswara Rao as Chairman & Managing Director saw mild dissent, with 100,033 votes (about 0.59%) against, mainly from public non-institutional shareholders (23.39% of public votes against). Appointment of Secretarial Auditors for a five-year term was also approved with 99.99% support.
This is a routine AGM outcome with all resolutions approved, so no immediate material impact on the stock is expected. The minor shareholder pushback on the CMD's re-appointment (around 24% of public votes against) is worth noting but is not significant enough to drive any change in company direction.